ERBB2 and breast carcinoma: This study led to the approval of olaparib by the FDA in the adjuvant setting of gBRCAMUT breast cancer patients [138], highlighting the importance of genetic testing in the surgical and medical treatment decision pathway in HER2-negative breast cancer [7].